Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is currently conducting a clinical study titled SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE. The study aims to assess the safety and effectiveness of upadacitinib, an oral treatment, in adult participants with moderate to severe systemic lupus erythematosus (SLE). The study’s significance lies in its potential to offer a new treatment option for SLE, a complex immune-mediated disease.
The intervention being tested is upadacitinib, an oral drug already approved for other inflammatory conditions such as rheumatoid arthritis. In this study, it is being evaluated for its potential to treat SLE by reducing disease activity and managing adverse events.
The study design is interventional, with participants randomly assigned to receive either upadacitinib or a placebo. The model is sequential, and the study is quadruple-masked, meaning neither participants nor care providers, investigators, or outcomes assessors know who receives the treatment. The primary purpose is treatment-focused.
The study began on July 19, 2023, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on June 24, 2025. These dates are crucial as they guide investors on the study’s progress and potential market entry timelines.
This clinical study update could positively impact AbbVie’s stock performance and investor sentiment, as successful results may expand the use of upadacitinib into the SLE market. This could position AbbVie favorably against competitors in the autoimmune treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.